VRDN Nilai Total Aset Perusahaan Viridian Therapeutics Inc

VRDN (Viridian Pharma) - tandha merek perusahaan

This price evolution chart on GURU.Markets shows that the total assets of Viridian Therapeutics (VRDN) amount to 839.83. The business relies on creating enhanced versions of popular drugs, focusing on antibodies for eye and thyroid therapies. The development of multiple promising drugs minimizes the probability of trial failure. The quality of biomolecules is guaranteed through the use of specialized transport systems with strict temperature control.

VRDN (Viridian Therapeutics) riwayat Total Aset Perusahaan saka 04.07.2022 nganti 31.10.2026

Rincian analitis lan laporan data perusahaan Viridian Pharma (VRDN)

- kuotasi lan prakiraan analis:
Kurs saham viridiantherapeutics.com|VRDN - Bagan rega target
- data kapitalisasi pasar:
Biji pasar Viridian Corp|VRDN - Nilai Perusahaan
- statistik nilai buku emiten:
Nilai Akuntansi Saham Viridian Therapeutics|VRDN - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku viridiantherapeutics.com|VRDN - Aset Agregat Perusahaan
- indikator beban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Viridian Therapeutics|VRDN - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Viridian Corp|VRDN - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Viridian Corp|VRDN - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Viridian Therapeutics|Likuiditas darurat viridiantherapeutics.com
- indikator pendapatan resik lan kelipatan nilai:
VRDN - Penghasilan resik
Pambiji fundamental:Viridian Therapeutics
Produk sing diprodhuksi Viridian Therapeutics

To find a balance between cost and business quality, it is essential to consider the total resources calculated reversely via ROA as the sum of equity and debt capital. This metric reflects the scale of the material base of Viridian Therapeutics (VRDN), where the company's volume of financial assets confirms the ability of this promising developer of targeted biologics for eye treatment to maintain high innovation intensity and operational resilience.

Pesaing wigati

Total Aset Bisnis ALC|Aset Agregat Perusahaan Bausch + Lomb|Glaukos Corp - Nilai Total Aset Perusahaan|Total Aset Perusahaan APLS|BLTE (Belite Bio Inc) - Nilai Agregat Aset|Total Aset Perusahaan OCUL (Ocular Therapeutix)|Total Aset Perusahaan harrowinc.com HROW|LENZ - Aset Agregat Perusahaan|Nilai Agregat Aset OCS (oculis.com)|EyePoint Pharma (EYPT) - Aset Agregat Perusahaan|Gunggung Aset Perusahaan Kodiak Corp|ALDX (Aldeyra Therapeutics Inc.) - Total Aset Perusahaan|Total Aset Perusahaan Kala Pharmaceuticals|Gunggung Aset Perusahaan IRD (Opus Genetics Inc)|OKYO (okyopharma.com) - Nilai Agregat Aset|Total Aset Perusahaan ADVM (Adverum Biotechnologies, Inc.)|Outlook Therapeutics Corp (OTLK) - Aset Perusahaan|CLSD: Gunggung Aset Perusahaan|Aset Perusahaan NovaBay Pharmaceuticals|KPRX: Total Aset Perusahaan|Aset Perusahaan Alimera Sciences, Inc. (ALIM)|Aset Agregat Perusahaan Eyenovia Inc.|Guardion Health (GHSI) - Gunggung Aset Perusahaan|Gunggung Aset Perusahaan OCUP (Ocuphire Pharma, Inc.)|Aset Agregat Perusahaan OPT (opthea.com)